Donor selection, graft engineering, and dosing oh my! Available to Purchase

3.

Crivello

P

,

Heinold

A

,

Rebmann

V

, et al.

Functional distance between recipient and donor HLA-DPB1 determines nonpermissive mismatches in unrelated HCT

.

Blood

.

2016

;

128

(

1

):

120

-

129

.

4.

Pidala

J

,

Lee

SJ

,

Ahn

KW

, et al.

Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation

.

Blood

.

2014

;

124

(

16

):

2596

-

2606

.

5.

Tram

K

,

Stritesky

G

,

Wadsworth

K

,

Ng

J

,

Anasetti

C

,

Dehn

J.

Identification of DPB1 permissive unrelated donors is highly likely

.

Biol Blood Marrow Transplant

.

2017

;

23

(

1

):

81

-

86

.

6.

Fleischhauer

K

,

Shaw

BE

,

Gooley

T

, et al;

International Histocompatibility Working Group in Hematopoietic Cell Transplantation

.

Effect of T-cell- epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study

.

Lancet Oncol

.

2012

;

13

(

4

):

366

-

374

.

7.

Saber

W

,

Opie

S

,

Rizzo

JD

,

Zhang

M-J

,

Horowitz

M-M

,

Schriber

J.

Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia

.

Blood

.

2012

;

119

(

17

):

3908

-

3916

.

8.

Spellman

SR

,

Xu

K

,

Oloyede

T

, et al.

Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy—a report from the CIBMTR

.

Transplant Cell Ther

.

2025

;

31

(

8

):

505

-

532

.

. https://wmda.info/storage/2025/10/CORRECTED-30072025-GTR-2024-Summary-Slides.pdf

9.

World Marrow Donor Association. WMDA | matching donors | serving patients

.

WMDA Global Trends Report 2024

10.

Petersdorf

EW

,

Bengtsson

M

,

De Santis

D

, et al;

International Histocompatibility Working Group in Hematopoietic-Cell Transplantation

.

Role of HLA-DP expression in graft-versus-host disease after unrelated donor transplantation

.

J Clin Oncol

.

2020

;

38

(

24

):

2712

-

2718

.

11.

Shaw

BE

,

Logan

BR

,

Spellman

SR

, et al.

Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most

.

Biol Blood Marrow Transplant

.

2018

;

24

(

5

):

1049

-

1056

.

12.

Nath

K

,

Zhang

M-J

,

Bye

M

, et al.

Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis

.

Blood Adv

.

2025

;

9

(

14

):

3469

-

3478

.

13.

Fuchs

EJ

,

O'Donnell

PV

,

Eapen

M

, et al.

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial

.

Blood

.

2021

;

137

(

3

):

420

-

428

.

14.

Elmariah

H

,

Fuchs

EJ

.

Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: mechanisms and results

.

Semin Hematol

.

2019

;

56

(

3

):

183

-

189

.

15.

Ciurea

SO

,

Al Malki

MM

,

Kongtim

P

, et al.

The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation

.

Bone Marrow Transplant

.

2020

;

55

(

1

):

12

-

24

.

16.

Ciurea

SO

,

de Lima

M

,

Cano

P

, et al.

High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation

.

Transplantation

.

2009

;

88

(

8

):

1019

-

1024

.

17.

Kongtim

P

,

Vittayawacharin

P

,

Zou

J

, et al.

ASTCT consensus recommendations on testing and treatment of patients with donor-specific anti-HLA antibodies

.

Transplant Cell Ther

.

2024

;

30

(

12

):

1139

-

1154

.

18.

Shaffer

BC

,

Gooptu

M

,

DeFor

TE

, et al.

Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors

.

J Clin Oncol

.

2024

;

42

(

28

):

3277

-

3286

.

19.

Raiola

AM

,

Bruno

B

,

Risitano

AM

, et al.

Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial

.

Blood Adv

.

2025

;

9

(

8

):

1966

-

1975

.

20.

Shaw

BE

,

Jimenez-Jimenez

AM

,

Burns

LJ

, et al.

National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide

.

J Clin Oncol

.

2021

;

39

(

18

):

1971

-

1982

.

21.

Al

Malki MM

,

Bo-Subait

S

,

Logan

B

, et al.

Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after mismatched unrelated donor peripheral blood stem cell transplantation

.

J Clin Oncol

.

2025

;

43

(

25

):

2772

-

2781

.

22.

Mehta

RS

,

Schmidt

G

,

Williams

K

, et al.

Choosing between HLA- mismatched unrelated and haploidentical donors: donor age considerations

.

Transplant Cell Ther

.

2025

;

31

(

9

):

680

-

692

.

23.

Politikos

I

,

Davis

E

,

Nhaissi

M

, et al;

American Society for Transplantation and Cellular Therapy Cord Blood Special Interest Group

.

Guidelines for cord blood unit selection

.

Biol Blood Marrow Transplant

.

2020

;

26

(

12

):

2190

-

2196

.

24.

Horwitz

ME

,

Stiff

PJ

,

Cutler

C

, et al.

Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study

.

Blood

.

2021

;

138

(

16

):

1429

-

1440

.

25.

Dumont-Lagacé

M

,

Feghaly

A

,

Meunier

M-C

, et al.

UM171 expansion of cord blood improves donor availability and HLA matching for all patients, including minorities

.

Transplant Cell Ther

.

2022

;

28

(

7

):

410.e1

-

410.e5

.

26.

Cohen

S

,

Bambace

N

,

Ahmad

I

, et al.

Improved outcomes of UM171- expanded cord blood transplantation compared with other graft sources: real-world evidence

.

Blood Adv

.

2023

;

7

(

19

):

5717

-

5726

.

27.

Anthias

C

,

Billen

A

,

Arkwright

R

,

Szydlo

RM

,

Madrigal

JA

,

Shaw

BE

.

Harvests from bone marrow donors who weigh less than their recipients are associated with a significantly increased probability of a suboptimal harvest yield

.

Transfusion

.

2016

;

56

(

5

):

1052

-

1057

.

28.

Jennifer Zhang

Q.

Donor selection based on NK alloreactivity for patients with hematological malignancies

.

Hum Immunol

.

2022

;

83

(

10

):

695

-

703

.

29.

Shaw

PJ

,

Kan

F

,

Woo Ahn

K

, et al.

Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors

.

Blood

.

2010

;

116

(

19

):

4007

-

4015

.

30.

de la Fuente

J

, et al.

Haploidentical bone marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative

.

Biol Blood Marrow Transplant

.

2019

;

25

(

6

):

1197

-

1209

.

31.

Klein

OR

,

Bapty

S

,

Lederman

HM

, et al.

Reduced intensity bone marrow transplantation with post-transplant cyclophosphamide for pediatric inherited immune deficiencies and bone marrow failure syndromes

.

J Clin Immunol

.

2021

;

41

(

2

):

414

-

426

.

32.

Bolaños-Meade

J

,

Hamadani

M

,

Wu

J

, et al;

BMT CTN 1703 Investigators

.

Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis

.

N Engl J Med

.

2023

;

388

(

25

):

2338

-

2348

.

33.

Ali

R

,

Ramdial

J

,

Algaze

S

,

Beitinjaneh

A

.

The role of anti-thymocyte globulin or alemtuzumab-based serotherapy in the prophylaxis and management of graft-versus-host disease

.

Biomedicines

.

2017

;

5

(

4

):

67

.

34.

Baron

F

,

Mohty

M

,

Blaise

D

, et al.

Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

.

Haematologica

.

2017

;

102

(

2

):

224

-

234

.

35.

Bonifazi

F

,

Rubio

M-T

,

Bacigalupo

A

, et al.

Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel

.

Bone Marrow Transplant

.

2020

;

55

(

6

):

1093

-

1102

.

36.

Dvorak

CC

,

Long-Boyle

JR

,

Holbrook-Brown

L

, et al.

Effect of rabbit ATG PK on outcomes after TCR-αβ/CD19-depleted pediatric haploidentical HCT for hematologic malignancy

.

Blood Adv

.

2024

;

8

(

23

):

6003

-

6014

.

37.

Leahy

AB

,

Li

Y

,

Talano

J-A

, et al.

Unrelated donor α/β T cell- and B cell- depleted HSCT for the treatment of pediatric acute leukemia

.

Blood Adv

.

2022

;

6

(

4

):

1175

-

1185

.

38.

Reisner

Y

,

Kapoor

N

,

Kirkpatrick

D

, et al.

Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells

.

Blood

.

1983

;

61

(

2

):

341

-

348

.

39.

Papadopoulos

EB

,

Carabasi

MH

,

Castro-Malaspina

H

, et al.

T-cell–depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease

.

Blood

.

1998

;

91

(

3

):

1083

-

1090

.

40.

Jakubowski

AA

,

Small

TN

,

Young

JW

, et al.

T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin

.

Blood

.

2007

;

110

(

13

):

4552

-

4559

.

41.

de Witte

M

,

Daenen

LGM

,

van der Wagen

L

, et al.

Allogeneic stem cell transplantation platforms with ex vivo and in vivo immune manipulations: count and adjust

.

Hemasphere

.

2021

;

5

(

6

):

e580

.

42.

Pasquini

MC

,

Devine

S

,

Mendizabal

A

, et al.

Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft- versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation

.

J Clin Oncol

.

2012

;

30

(

26

):

3194

-

3201

.

43.

Barba

P

,

Hilden

P

,

Devlin

SM

, et al.

Ex vivo CD34(+)-selected T cell-depleted peripheral blood stem cell grafts for allogeneic hematopoietic stem cell transplantation in acute leukemia and myelodysplastic syndrome is associated with low incidence of acute and chronic graft-versus-host disease and high treatment response

.

Biol Blood Marrow Transplant

.

2017

;

23

(

3

):

452

-

458

.

44.

Bayraktar

UD

,

de Lima

M

,

Saliba

RM

, et al.

Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission

.

Biol Blood Marrow Transplant

.

2013

;

19

(

6

):

898

-

903

.

45.

Devine

SM

,

Carter

S

,

Soiffer

RJ

, et al.

Low risk of chronic graft-versus-host disease and relapse associated with T cell–depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303

.

Biol Blood Marrow Transplant

.

2011

;

17

(

9

):

1343

-

1351

.

46.

Luznik

L

,

Pasquini

MC

,

Logan

B

, et al.

Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies

.

J Clin Oncol

.

2022

;

40

(

4

):

356

-

368

.

47.

Rachamim

N

,

Gan

J

,

Segall

H

, et al.

Tolerance induction by “megadose” hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture

.

Transplantation

.

1998

;

65

(

10

):

1386

-

1393

.

48.

Aversa

F

,

Terenzi

A

,

Tabilio

A

, et al.

Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse

.

J Clin Oncol

.

2005

;

23

(

15

):

3447

-

3454

.

49.

Handgretinger

R

,

Klingebiel

T

,

Lang

P

, et al.

Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children

.

Bone Marrow Transplant

.

2001

;

27

(

8

):

777

-

783

.

50.

Chakraverty

R

,

Robinson

S

,

Peggs

K

, et al.

Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation

.

Bone Marrow Transplant

.

2001

;

28

(

9

):

827

-

834

.

51.

Lang

P

,

Handgretinger

R

,

Niethammer

D

, et al.

Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia

.

Blood

.

2003

;

101

(

4

):

1630

-

1636

.

52.

Dvorak

CC

,

Gilman

AL

,

Horn

B

, et al.

Haploidentical related-donor hematopoietic cell transplantation in children using megadoses of CliniMACs- selected CD34(+) cells and a fixed CD3(+) dose

.

Bone Marrow Transplant

.

2013

;

48

(

4

):

508

-

513

.

53.

Bunin

N

,

Aplenc

R

,

Grupp

S

,

Pierson

G

,

Monos

D.

Unrelated donor or partially matched related donor peripheral stem cell transplant with CD34+ selection and CD3+ addback for pediatric patients with leukemias

.

Bone Marrow Transplant

.

2006

;

37

(

2

):

143

-

149

.

54.

Seif

AE

,

Li

Y

,

Monos

DS

, et al.

Partially CD3+-depleted unrelated and haploidentical donor peripheral stem cell transplantation has favorable graft-versus-host disease and survival rates in pediatric hematologic malignancy

.

Biol Blood Marrow Transplant

.

2020

;

26

(

3

):

493

-

501

.

55.

Chaleff

S

,

Otto

M

,

Barfield

RC

, et al.

A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation

.

Cytotherapy

.

2007

;

9

(

8

):

746

-

754

.

56.

Locatelli

F

,

Merli

P

,

Pagliara

D

, et al.

Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletion

.

Blood

.

2017

;

130

(

5

):

677

-

685

.

57.

Pulsipher

MA

,

Ahn

KW

,

Bunin

NJ

, et al.

KIR-favorable TCR-αβ/CD19- depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial

.

Blood

.

2022

;

140

(

24

):

2556

-

2572

.

58.

Merli

P

,

Algeri

M

,

Galaverna

F

, et al.

TCRαβ/CD19 cell-depleted HLA- haploidentical transplantation to treat pediatric acute leukemia: updated final analysis

.

Blood

.

2024

;

143

(

3

):

279

-

289

.

59.

Bleakley

M

,

Sehgal

A

,

Seropian

S

, et al.

Naive T-cell depletion to prevent chronic graft-versus-host disease

.

J Clin Oncol

.

2022

;

40

(

11

):

1174

-

1185

.

60.

Oliai

C

,

Hoeg

RT

,

Pavlova

A

, et al.

Precision-engineered cell therapy orca-T demonstrates high relapse-free survival at 1 year while reducing graft- versus-host disease and toxicity

.

Blood

.

2022

;

140

(

suppl 1

):

654

-

656

.

61.

Plenary Abstracts Session & Oral Presentations

.

HemaSphere

.

2025

;

9

(suppl

1

):

e70151

.

62.

Wada

F

,

Iwasaki

M

,

Hirayama

M

, et al.

Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation

.

Leukemia

.

2025

;

39

(

4

):

951

-

961

.

63.

Maffini

E

,

Labopin

M

,

Blaise

D

, et al.

CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

.

Am J Hematol

.

2020

;

95

(

8

):

892

-

899

.

64.

Takahashi

T

,

Prockop

SE

.

T-cell depleted haploidentical hematopoietic cell transplantation for pediatric malignancy

.

Front Pediatr

.

2022

;

10

:

987220

.

65.

Singhal

S

,

Powles

R

,

Treleaven

J

, et al.

A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 10(6) CD34+ cells/kg be considered the minimum threshold?

Bone Marrow Transplant

.

2000

;

26

(

5

):

489

-

496

.

66.

Morariu-Zamfir

R

,

Rocha

V

,

Devergie

A

, et al.

Influence of CD34(+) marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia

.

Bone Marrow Transplant

.

2001

;

27

(

6

):

575

-

580

.

67.

Pulsipher

MA

,

Chitphakdithai

P

,

Logan

BR

, et al.

Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose

.

Blood

.

2009

;

114

(

13

):

2606

-

2616

.

68.

Czerw

T

,

Labopin

M

,

Schmid

C

, et al.

High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia—an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

.

Oncotarget

.

2016

;

7

(

19

):

27255

-

27266

.

69.

Morishima

Y

,

Watanabe-Okochi

N

,

Kai

S

, et al.

Selection of cord blood unit by CD34+ Cell and GM-CFU numbers and allele-level HLA matching in single cord blood transplantation

.

Transplant Cell Ther

.

2023

;

29

(

10

):

622

-

631

.